Profound Medical Q2 FY26 net loss narrows 39% to USD 9.5 million; revenue rises 12% to USD 2.5 million
PROF•Q2 revenue and loss improve
Profound Medical Q2 total revenue rose 12% year over year to USD 2.5 million; net loss narrowed 39% to USD 9.5 million (USD 0.26/share).
Gross margin expanded 5 percentage points to 78%; operating expenses fell 16% to USD 13 million.
Full-year outlook reiterated
Full-year 2026 revenue guidance reiterated at about USD 25 million; expects gross margin of 70% or higher.
Installed base and pipeline grow
TULSA-PRO installed base increased to 84; qualified sales pipeline estimated at about USD 70 million.
Shipment timing shifts TULSA revenue into Q3
About USD 3.1 million of TULSA revenue recognition shifted into early Q3 due to shipment timing; Q2 capital equipment sales were USD 871,000.
